Our People

Tina Sampath

CEO

Tina is an award-winning executive with over 26 years of experience and a proven track record of creating growth and profitability within top life sciences companies, including Gilead Sciences through the acquisition of CV Therapeutics in 2009 for $1.4B, Pfizer through the acquisition of Medivation in 2016 for $14B, and Blue Earth Diagnostics which exited to Bracco in 2019 for $476M. Passionate about the intersection of health and technology, Tina transitioned to MedTech where she served as VP, Enterprise Marketing at AliveCor. In this role, she was responsible for driving growth across multiple B2B business units.

Tina joined Cumulus as CCO in 2023 and was charged with driving growth for the company’s first product, the NeuLogiq® Platform. Tina assumed the role of Interim CEO in 2024 and was confirmed as CEO in 2025. Tina is responsible for driving the continued growth of NeuLogiq in the biopharma CNS clinical development space.

Brian Murphy, PhD

Co-founder & CSO

Brian is a computational neuroscientist who is an expert in brain-reading technology, using machine learning methods to decode cognitive states from recordings of brain activity (EEG, fMRI, MEG) and other data.

His academic career included positions as assistant professor in Data Science at Queen's University Belfast, as senior researcher at Carnegie Mellon University’s Department of Machine learning, the world’s leading lab for applying machine learning to brain activity, and as post-doc at the Centre for Mind/Brain Sciences, University of Trento, Italy, one of Europe’s leading cognitive neuroscience centres. He has a Ph.D. in Cognitive Science from Trinity College Dublin and prior to academia, worked in and co-founded web startups in Germany and China. Brian is a member of the Alzheimer’s Association EEG PIA committee, and organised the MLINI series of workshops on machine learning with neuroimaging data at NeurIPS, the world’s leading machine learning conference.

Siggi Saevarsson

COO

Siggi has over 20 years of experience in C-level management of fast-growing technology startups, scaleups, and venture capital investing. He has worked directly for Intel Corporation, Nokia, OpenWave Systems, and several telco startups. Before joining Cumulus, Siggi was a Partner at Kernel Capital, a leading Irish Venture Capital Fund. Siggi has a degree in Computer Science and Business Administration from Copenhagen Business School and studied at Carnegie Mellon University.

Terry Reilly

SVP, Global Business Development

With over three decades of experience in life sciences and business development, Terry leads global business development efforts at Cumulus. His focus is on advancing digital neuroscience solutions to improve CNS disorder outcomes by fostering strategic partnerships and driving revenue growth.  

Terry brings expertise in direct sales, teamwork, and leadership development to guide a high-performing global team. His mission is to expand commercial reach across key CNS indications while building strong relationships with Biopharma teams.

Alexandra Cowden

Head of Quality

Alexandra is a results-driven Quality Professional with extensive experience in implementing and managing UK MDR, EU MDR/IVDR, and FDA-compliant Quality Management Systems (QMS) within medical device and in vitro diagnostic (IVD) industries since 2017.

Alexandra brings a strong background in quality assurance, risk management, and continuous improvement, with a proven track record of aligning quality objectives with organisational strategy. Her work is driven by a commitment to patient/user safety, product integrity, and quality and regulatory excellence. She has a Bachelor of Science in Biology from Ulster University.

Ian McCullough

Head of Product

Ian is an accomplished product leader with over 20 years of experience in the medical device industry. After receiving his Master’s in Electronic Systems from the University of Ulster, he spent a short time in the semiconductor industry before pursuing his passion: building innovative medical products.

During his 14 years at Intelesens Ltd, Ian gained extensive technical knowledge in vital signs data capture and analysis, including ECG, respiration, temperature, SpO2, and blood pressure monitoring. He has a proven track record of guiding products from early-stage discovery through to launch, ensuring compliance with FDA 510(k) and CE standards. At Cumulus Neuroscience, Ian’s strategic vision, leadership, and commitment to excellence drive product innovation. His dedication to creating impactful medical products ensures that every development focuses on delivering a seamless user experience while significantly impacting patients’ health and wellbeing.

Ricardo Sáinz Fuertes
MD, MSc, Ph.D, FRCPsych, EDTX

Chair

With nearly two decades in psychiatry and over a decade in the pharma industry, Ricardo specializes in advancing digital biomarkers, digital therapeutics, and neuroscience-driven solutions that improve diagnosis, treatment, and patient outcomes.

Tina Sampath

Director

Tina is an award-winning executive with over 26 years of experience and a proven track record of creating growth and profitability within top life sciences companies, including Gilead Sciences through the acquisition of CV Therapeutics in 2009 for $1.4B, Pfizer through the acquisition of Medivation in 2016 for $14B, and Blue Earth Diagnostics which exited to Bracco in 2019 for $476M. Passionate about the intersection of health and technology, Tina transitioned to MedTech where she served as VP, Enterprise Marketing at AliveCor. In this role, she was responsible for driving growth across multiple B2B business units.

Tina joined Cumulus as CCO in 2023 and was charged with driving growth for the company’s first product, the NeuLogiq® Platform. Tina assumed the role of Interim CEO in 2024 and was confirmed as CEO in 2025. Tina is responsible for driving the continued growth of NeuLogiq in the biopharma CNS clinical development space.

Brian Murphy, PhD

Co-founder & Director

Brian is a computational neuroscientist who is an expert in brain-reading technology, using machine learning methods to decode cognitive states from recordings of brain activity (EEG, fMRI, MEG) and other data.

His academic career included positions as assistant professor in Data Science at Queen's University Belfast, as senior researcher at Carnegie Mellon University’s Department of Machine learning, the world’s leading lab for applying machine learning to brain activity, and as post-doc at the Centre for Mind/Brain Sciences, University of Trento, Italy, one of Europe’s leading cognitive neuroscience centres. He has a Ph.D. in Cognitive Science from Trinity College Dublin and prior to academia, worked in and co-founded web startups in Germany and China. Brian is a member of the Alzheimer’s Association EEG PIA committee, and organised the MLINI series of workshops on machine learning with neuroimaging data at NeurIPS, the world’s leading machine learning conference.

Graham Ferguson

Director

Graham has proven expertise in developing and executing strategic transformation programmes, debt and equity fundraising, and leading large, complex, international M&A.

Brian Cummings

Director

Brian is an Investment Director with Clarendon Fund Managers where he is responsible for CoFundNI investments into multiple portfolio companies. Previously he spent 9 years at Enterprise Equity, a Belfast based VC & PE investment house.

Robert Ballantine

Director

Robert leads IQVIA's global Digital Health Center of Excellence, driving the strategy and integration of digital health solutions across pharmaceutical, medtech, and healthcare ecosystems. He brings more than 27 years' experience in innovation and human-centred design, with deep expertise in translating emerging technologies into clinically meaningful, operationally scalable solutions. His recent research and consulting interests centre on the role of digital innovation in neurology and cardiometabolic disease — spanning wearable technologies, digital biomarkers, and data-driven care models that support prevention, earlier intervention, and improved patient outcomes.